Lexeo Therapeutics, Common Stock Price To Sales
| LXEO Stock | 7.83 0.50 6.82% |
Lexeo Therapeutics, Common fundamentals help investors to digest information that contributes to Lexeo Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Lexeo Stock. The fundamental analysis module provides a way to measure Lexeo Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lexeo Therapeutics, stock.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 435.94 | 369.18 |
Lexeo | Price To Sales |
Lexeo Therapeutics, Common Company Price To Sales Analysis
Lexeo Therapeutics,'s Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Lexeo Therapeutics, Price To Sales | 369.18 |
Most of Lexeo Therapeutics,'s fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lexeo Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lexeo Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for Lexeo Therapeutics, is extremely important. It helps to project a fair market value of Lexeo Stock properly, considering its historical fundamentals such as Price To Sales. Since Lexeo Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lexeo Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lexeo Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Lexeo Price To Sales Historical Pattern
Today, most investors in Lexeo Therapeutics, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lexeo Therapeutics,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Lexeo Therapeutics, price to sales as a starting point in their analysis.
Lexeo Therapeutics, Price To Sales |
| Timeline |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Lexeo Price To Sales Ratio
Price To Sales Ratio |
|
Lexeo Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lexeo Therapeutics,'s direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lexeo Therapeutics, could also be used in its relative valuation, which is a method of valuing Lexeo Therapeutics, by comparing valuation metrics of similar companies.Lexeo Therapeutics, is currently under evaluation in price to sales category among its peers.
Lexeo Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lexeo Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lexeo Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Lexeo Fundamentals
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 112.29 M | ||||
| Shares Outstanding | 33.06 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 91.48 % | ||||
| Number Of Shares Shorted | 2.49 M | ||||
| Price To Book | 1.86 X | ||||
| EBITDA | (66.67 M) | ||||
| Net Income | (66.39 M) | ||||
| Total Debt | 11.64 M | ||||
| Book Value Per Share | 4.99 X | ||||
| Cash Flow From Operations | (59.5 M) | ||||
| Short Ratio | 6.55 X | ||||
| Earnings Per Share | (12.53) X | ||||
| Target Price | 22.43 | ||||
| Number Of Employees | 69 | ||||
| Market Capitalization | 254.24 M | ||||
| Total Asset | 139.81 M | ||||
| Retained Earnings | (181.84 M) | ||||
| Working Capital | 107.06 M | ||||
| Net Asset | 139.81 M |
About Lexeo Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lexeo Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexeo Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexeo Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Lexeo Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lexeo Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexeo Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving together with Lexeo Stock
| 0.69 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.85 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.79 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Lexeo Stock
| 0.81 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.66 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.36 | MNOV | MediciNova | PairCorr |
| 0.34 | PHVS | Pharvaris BV | PairCorr |
The ability to find closely correlated positions to Lexeo Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lexeo Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lexeo Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lexeo Therapeutics, Common to buy it.
The correlation of Lexeo Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lexeo Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lexeo Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lexeo Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Lexeo Therapeutics, Piotroski F Score and Lexeo Therapeutics, Altman Z Score analysis. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexeo Therapeutics,. If investors know Lexeo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexeo Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.53) | Return On Assets (0.40) | Return On Equity (0.75) |
The market value of Lexeo Therapeutics, is measured differently than its book value, which is the value of Lexeo that is recorded on the company's balance sheet. Investors also form their own opinion of Lexeo Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Lexeo Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexeo Therapeutics,'s market value can be influenced by many factors that don't directly affect Lexeo Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexeo Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexeo Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexeo Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.